Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 1 de 1
Filter
Add more filters

Database
Language
Journal subject
Affiliation country
Publication year range
1.
Ren Fail ; 45(1): 2238831, 2023 Dec.
Article in English | MEDLINE | ID: mdl-37482748

ABSTRACT

Acute kidney injury (AKI) and renal interstitial fibrosis are global clinical syndromes associated with high morbidity and mortality. Renal ischemia-reperfusion (I/R) injury, which commonly occurs during surgery, is one of the major causes of AKI. Nevertheless, an efficient therapeutic approach for AKI and the development of renal interstitial fibrosis is still lacking due to its elusive pathogenetic mechanism. Here, we showed that chitosan oligosaccharide (COS), a natural oligomer polysaccharide degraded from chitosan, significantly attenuates I/R-induced AKI and maintains glomerular filtration function by inhibiting oxidative stress, mitochondrial damage, and excessive endoplasmic reticulum stress both in vitro and in vivo. In addition, long-term administration of COS can also attenuate the proliferation of myofibroblasts, mitigate extra cellular matrix deposition, and thus inhibit the transition of AKI to chronic kidney disease through participating in metabolic and redox biological processes. Our findings provide novel insights into the protective role of COS against acute kidney injury.


Subject(s)
Acute Kidney Injury , Chitosan , Reperfusion Injury , Humans , Chitosan/pharmacology , Chitosan/therapeutic use , Chitosan/metabolism , Acute Kidney Injury/drug therapy , Acute Kidney Injury/etiology , Acute Kidney Injury/prevention & control , Kidney/pathology , Ischemia , Reperfusion Injury/complications , Reperfusion Injury/drug therapy , Reperfusion Injury/metabolism , Reperfusion/adverse effects , Fibrosis , Oligosaccharides/pharmacology , Oligosaccharides/therapeutic use , Oligosaccharides/metabolism
SELECTION OF CITATIONS
SEARCH DETAIL